The viability of ABO-incompatible kidney transplants: a single-center cohort in China
In this Chinese single-center cohort, ABOi-LDKT achieved short- to mid-term clinical outcomes comparable to ABOc-LDKT despite higher upfront costs. When combined with contemporary desensitization protocols, ABOi-LDKT appears to be a safe and feasible strategy to expand access to living donor kidney transplantation in settings with severe organ shortages.
Authors
- P. LI
- Yiding Chen
- Jinbiao Zhong
- Dongsheng Li (ORCID: https://orcid.org/0000-0001-5348-4764)
- Guiyi Liao (ORCID: https://orcid.org/0000-0002-6299-9505)
- Wenbo Wang (ORCID: https://orcid.org/0009-0008-4377-2752)
- Handong Ding
- Jiashan Pan
- Fei Zhang
- Kun Wang
Institutions
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.3389/fimmu.2026.1747411
- Primary Topic
- Organ Donation and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Anhui Medical University